Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IVIM-DWI for Early Therapeutic Effect Assessment of Chemotherapy Combined With Anti-Angiogenic Drugs for Colorectal Cancer Liver Metastases

ABSTRACT: Interventions: CapeOX + Bevacizumab Chemotherapy Response Group:None;CapeOX + Bevacizumab Chemotherapy Non-response Group:None Primary outcome(s): perfusion fraction (f);true diffusion coefficient (D);true diffusion coefficient (D);false diffusion coefficient (D*);false diffusion coefficient (D*) Study Design: Factorial

DISEASE(S): Colorectal Cancer

PROVIDER: 35217 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab

Project description:Bevacizumab represents anti-angiogenic effect in cancer patients by inhibiting vascular endothelial growth factor (VEGF). However, its use is still limited due to the resistance to the initial response. Such resistance could be regulated by various cell types and soluble factors, although the underlying mechanisms, especially cell-based mechanisms, remain incompletely understood. Here, we identified bone marrow-derived fibrocytes as a novel contributor for the acquired resistance to bevacizumab, defined as alpha-1 type I collagen-positive and CXCR4-positive cells. In mouse models of lung cancer and malignant pleural mesothelioma, fibrocytes mediated the resistance to bevacizumab as a main producer of fibroblast growth factor 2. Using clinical specimens of lung cancer that were surgically resected after bevacizumab treatment, we demonstrated that the number of fibrocytes was significantly increased in bevacizumab-treated tumor, and was correlated with the number of treatment cycles as well as CD31-positive vessels. Our results identify fibrocytes as a promising cell biomarker and a potential therapeutic target to overcome resistance to anti-VEGF therapy.

2015-12-03 | GSE59476 | GEO

Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer

Project description:The primary objective of this study is to correlate the percentage change in apparent diffusion coefficient (ADC) between baseline and early therapy (at day 14) with tumor regression grade (TRG) measured in the surgical resection specimen.

| 2183216 | ecrin-mdr-crc

REAL-TIME VASCULAR ANATOMICAL IMAGE NAVIGATION FOR LAPAROSCOPIC SURGERY: A RETROSPECTIVE FEASIBILITY STUDY

Project description:Interventions: Single arm:None Primary outcome(s): Dice Similarity Coefficient Study Design: Single arm

| 2715961 | ecrin-mdr-crc

Transcription profiling by array of mouse primary hepatocytes under treatment of genotoxic compounds.

Project description:Gene expression profiling in primary mouse hepatocytes discriminates true from false-positive genotoxic compounds with addtional compounds

2011-03-22 | E-MEXP-2636 | biostudies-arrayexpress

Anti-Angiogenic Activity of Drugs in Multiple Myeloma.

Project description:Angiogenesis represents a pivotal hallmark of multiple myeloma (MM) that correlates to patients' prognosis, overall survival, and drug resistance. Hence, several anti-angiogenic drugs that directly target angiogenic cytokines (i.e., monoclonal antibodies, recombinant molecules) or their cognate receptors (i.e., tyrosine kinase inhibitors) have been developed. Additionally, many standard antimyeloma drugs currently used in clinical practice (i.e., immunomodulatory drugs, bisphosphonates, proteasome inhibitors, alkylating agents, glucocorticoids) show anti-angiogenic effects further supporting the importance of inhibiting angiogenesis from potentiating the antimyeloma activity. Here, we review the most important anti-angiogenic therapies used for the management of MM patients with a particular focus on their pharmacological profile and on their anti-angiogenic effect in vitro and in vivo. Despite the promising perspective, the direct targeting of angiogenic cytokines/receptors did not show a great efficacy in MM patients, suggesting the need to a deeper knowledge of the BM angiogenic niche for the design of novel multi-targeting anti-angiogenic therapies.

| S-EPMC10093708 | biostudies-literature

Transcription profiling in primary mouse hepatocytes discriminates between true and false genotoxic compounds

Project description:Primary mouse hepatocytes are applied in this study as an in vitro system to discriminate false positive GTX compounds from true GTX compounds.

2011-01-11 | E-MEXP-2539 | biostudies-arrayexpress